Cross-linked lipoic acid nanoparticles with indole-3-methanol loading for the PTEN-me diate d TNBC treatment  

作　　者：Xiao Xiao Rong Cui Chunyan Liao Shiyong Zhang 

机构地区：[1]College of Biomedical Engineering and National Engineering Research Center for Biomaterials,Sichuan University,Chengdu 610064,China

出　　处：《Journal of Materials Science & Technology》2024年第14期198-208,共11页材料科学技术（英文版）

基　　金：supported by the National Natural Science Foundation of China(Nos.22275129 and 21975165);the Innovative Research Team Program of Sichuan Province(No.2021JDTD0015);the Sichuan University Postdoctoral Interdisciplinary Innovation Fund(No.2022SCU12106).

摘　　要：We here report a non-gene therapy anti-tumor nanoparticles(I3C@cLANPs)based PTEN by loading indole-3-methanol(I3C)into the cross-linked lipoic acid nanoparticles(cLANPs)for triple-negative breast cancer(TNBC)treatment.I3C is a PTEN-specific natural activator while the poor PTEN-activation effi-ciency impedes its ability to achieve the PTEN-mediated tumor therapy.Due to the structural homology of lipoic acid(LA),the cLANPs hold not only LA-like anticancer activity but also PTEN-activation proper-ties,which would synergistically potentiate the PTEN-activation efficiency.The in vitro and in vivo data showed that PTEN expression in the I3C@cLANPs group was 2.1 and 2.8 times higher than that of I3C,respectively.In antitumor evaluation based on the 4T1 tumor-bearing mice showed a tumor inhibitory rate(TIR)of 78.4%at the I3C usage of 20 mg kg^(–1),54.5%higher than that of I3C alone and 19.7%higher than that of first-line chemotherapy drug Doxorubicin hydrochloride(DOX).Thus,the I3C@cLANPs could address the low activation efficiency in the PTEN-mediated tumor strategy and avoid the risks of gene therapy,holding a good prospect for TNBC and related cancer treatment.

关 键 词：Triple-negative breast cancer Indole-3-methanol Lipoic acid Synergistic therapy 

分 类 号：TB383.1[一般工业技术—材料科学与工程] O641.4[理学—物理化学]